{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:28:03Z","timestamp":1790047683147,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":3588,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1111\/j.1469-0691.2004.01051.x","type":"journal-article","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T12:04:33Z","timestamp":1106741073000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres"],"prefix":"10.1016","volume":"11","author":[{"given":"A.C.","family":"Gales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2004.01051.x_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jcp.14.4.385","article-title":"Methicillin-resistant staphylococci","volume":"14","author":"Barber","year":"1961","journal-title":"J Clin Pathol"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2004.01051.x_bib2","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1201-9712(00)90098-5","volume":"4","author":"Gales","year":"2000","journal-title":"Int J Infect Dis"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2004.01051.x_bib4","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1086\/320185","article-title":"Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999","volume":"32","author":"Low","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200464090-00001","article-title":"Glycopeptide antibiotics: from conventional molecules to new derivatives","volume":"64","author":"Van Bambeke","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.33.1.10","article-title":"Transferable vancomycin and teicoplanin resistance in Enterococcus faecium","volume":"33","author":"Leclercq","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib8","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.45.7.2154-2156.2001","article-title":"Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci","volume":"45","author":"Prystowsky","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1179\/joc.2001.13.3.244","article-title":"In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent","volume":"13","author":"Jones","year":"2001","journal-title":"J Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib12","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","article-title":"In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib14","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib15","series-title":"Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib16","series-title":"Performance standard for antimicrobial susceptibility testing","author":"National Committee for Clinical Laboratory Standards","year":"2004"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543784.12.2.117","article-title":"Novel agents for the treatment of resistant Gram-positive infections","volume":"12","author":"Woodford","year":"2003","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0732-8893(03)00012-9","article-title":"Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial surveillance Program (1997-2000)","volume":"46","author":"Mutnick","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0732-8893(02)00511-4","article-title":"Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization","volume":"45","author":"Andrade-Baiocchi","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib21","series-title":"Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents","article-title":"The emergence of linezolid-resistance among Staphylococcus aureus from cystic fibrosis patients [abstract C2-1825]","author":"Andrade","year":"2003"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/AAC.48.4.1118-1123.2004","article-title":"Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model","volume":"48","author":"Jabes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.01051.x_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14622060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14622060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:14:46Z","timestamp":1761117286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14622060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S1198743X14622060"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.01051.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.01051.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}